ST. LOUIS, Aug. 8 /EMWNews/ -- Stereotaxis, Inc. (Nasdaq:

STXS), announced today the appointment of Michael P. Kaminski, 48,

President and Chief Operating Officer of Stereotaxis, to the Company's

Board of Directors. This appointment brings the total number of directors

serving on the Stereotaxis Board to 11.



    "We are very pleased to announce Mike's election to the Stereotaxis

Board," said Fred Middleton, Chairman of the Stereotaxis Board of

Directors. "He continues to play a key role for us in the planning and

execution of our commercial growth strategy. This will take on increasing

significance at Stereotaxis as we prepare to expand the utilization of our

innovative technology through several new product introductions into what

is becoming an expanding world-wide market."



    Bevil Hogg, Chief Executive Officer for Stereotaxis, added, "Under

Mike's operational leadership, Stereotaxis has successfully positioned

itself as a leader in innovative interventional robotic systems. He will

strengthen our focus on building Stereotaxis into a successful commercial

enterprise from an early stage technology company."



    Mr. Kaminski joined Stereotaxis in April 2002 as its Chief Operating

Officer. He was named to the additional position of President in 2007.

Prior to joining the Company, Mr. Kaminski spent nearly 20 years with

Hill-Rom Company, a leading worldwide manufacturer and provider of medical

technologies and related services for the health care industry. In his last

position there as Senior Vice President of North American Sales and

Service, he was responsible for 150 service centers, and revenue exceeding

$750 million. Mr. Kaminski began his career at Hill-Rom in a manufacturing

management position and then worked in several functional departments,

including sales, marketing, purchasing, new product development, and

general management of multiple businesses. Mr. Kaminski has an M.B.A. from

Xavier University and a B.S. in Marketing from Indiana University.

    About Stereotaxis



    Stereotaxis designs, manufactures and markets an advanced cardiology

instrument control system for use in a hospital's interventional surgical

suite to enhance the treatment of coronary artery disease and arrhythmias.

The Stereotaxis System is designed to enable physicians to complete more

complex interventional procedures by providing image guided delivery of

catheters and guidewires through the blood vessels and chambers of the

heart to treatment sites. This is achieved using computer-controlled,

externally applied magnetic fields that govern the motion of the working

tip of the catheter or guidewire, resulting in improved navigation, shorter

procedure time and reduced x-ray exposure. The core components of the

Stereotaxis system have received regulatory clearance in the U.S., Europe

and Canada.